10x Science, an AI drug discovery startup, raises $4.8M seed.

10x Science, an AI-powered drug discovery startup, has raised $4.8 million in seed funding. The round was led by Mitsubishi UFJ Innovation Partners (MUIP), a Japanese venture capital firm. The company aims to accelerate early-stage drug development using machine learning to identify promising therapeutic candidates, particularly focusing on small molecules and antibody design.

In the AI-for-drug-discovery sector, seed rounds are increasingly common as capital flows into early-stage biotech AI applications, but the space is becoming crowded. 10x Science competes with larger players like Recursion Pharmaceuticals, Insilico Medicine, and Atomwise, which have deeper war chests and more established pipelines. The MUIP backing, a corporate VC from a major Japanese financial group, signals a strategic interest in leveraging AI to reshape pharma R&D in Japan—a market where government initiatives are actively promoting digital health innovation.

While $4.8M is modest relative to the multi-hundred-million-dollar rounds of top-tier AI biotech companies, this seed funding fits a recurring pattern of smaller, focused startups emerging to address specific bottlenecks in drug discovery. The challenge for 10x Science will be to demonstrate enough validation—either via partnerships or early candidate milestones—to attract subsequent, larger rounds in a capital-intensive industry. For now, this is an incremental addition to the growing roster of AI-first biotechs.